Join Team CFCanada for the Scotiabank Toronto Waterfront Marathon (STWM) with both in-person and virtual race options!
*See event listing for more information*Read More
Did you know that your version of Internet Explorer is out of date?
To get the best possible experience using our website we recommend downloading one of the browsers below.
The pan-Canadian Pharmaceutical Alliance (pCPA) pCPA is an alliance made up of drug program leaders from all provincial, territorial and federal governments who work collaboratively to negotiate drug prices for their respective programs. Its pricing decisions are a precondition of having a medication covered on provincial drug formularies.
When a drug comes to Canada it must go through the Canadian drug regulatory, review and reimbursement system. The drug must go to various review bodies before it is eligible for public reimbursement. The pCPA is the last stage before public health plans decide whether or not to list a drug.
All Canadian provinces provide coverage for Kalydeco for those with a specific mutation (the G551D mutation) on an exceptional, case-by-case basis. In 2019, the pCPA and the manufacturer completed price negotiations for additional Kalydeco mutations, which unfortunately are still not covered by most public drug programs.
In June 2021, the pan Canadian Pharmaceutical Alliance (pCPA) announced that they had successfully concluded negotiations with Vertex for Kalydeco and Orkambi, for all Health Canada approved mutations. They also mentioned that upon approval from Health Canada and a finalized recommendation from CADTH, they may choose to add Trikafta to their agreement.
For more information please see the Q&A.
The Cystic Fibrosis Canada is calling all provincial ministries of Health to: